Is Puma Biotechnology, Inc. (PBYI) Overvalued?
We dive into why Puma Biotechnology, Inc. (PBYI) could be considered overvalued on 2026-08-14, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Commentary & Analysis
Why Puma Biotechnology, Inc.’s (PBYI) Stock Is Up 10.34%
As of Friday, August 07, Puma Biotechnology, Inc.’s PBYI share price has surged by 10.34%, which has investors questioning if this is right time to sell.Rosalio Madrigal
5 Undervalued Biotechnology Stocks for Friday, July 31
Discover the top 5 undervalued Biotechnology stocks for Friday, July 31 based on AAII’s Stock Grades.Michael Rose
Why Puma Biotechnology, Inc.’s (PBYI) Stock Is Up 5.35%
As of Friday, June 26, Puma Biotechnology, Inc.’s PBYI share price has surged by 5.35%, which has investors questioning if this is right time to sell.Rosalio Madrigal
3 Undervalued Biotechnology Stocks for Thursday, June 18
Discover the top 3 undervalued Biotechnology stocks for Thursday, June 18 based on AAII’s Stock Grades.Michael Rose
Financial Summary
| Share Statistics | PBYI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $473.4 | $272.7 | 36% |
|
| Shares Out (Mil) | 52.6 | 54.1 | 49% |
|
| Institutional Ownership | 81.6% | 93.0% | 50% |
|
| Float (Mil) | 39.6 | 42.3 | 42% |
|
| Beta | 1.22 | 0.95 | 72% |
|
| Avg Daily Volume (000s) | 297 | 471 | 51% |
|
| Price Change (52-week) |
94.7% | 56.7% | 92% |
|
| Growth | PBYI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 0.3% | 14.1% | 18% |
|
| Net Income (5yr) | 20.3% | (10.1%) | 74% |
|
| EPS (5yr) | 19.1% | 15.7% | 66 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (26.9%) | (15.6%) | 23% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PBYI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $231 | $37 | 33% |
|
| Net Income (TTM) (Mil) | $27 | ($43) | 51% |
|
| EPS (TTM) | $0.528 | ($1.600) | 54% |
|
| Operating Cash Flow (TTM) (Mil) | $41 | ($31) | 45% |
|
| Net Cash Flow (TTM) (Mil) | ($20) | $2 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $4 | 24% |
|
| Enterprise Value (Q1) (Mil) | $360 | $185 | 31% |
|
| Valuation | PBYI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.38 | 2.68 | 69% |
|
| P/E | 18.2 | 19.6 | 48% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 1.0 | 1.0 | 45% |
|
| Ratios | PBYI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 74.8% | 67.6% | 85% |
|
| Net Margin | 11.6% | (73.5%) | 66% |
|
| ROA | 13.8% | (47.9%) | 92% |
|
| ROE | 22.0% | (55.0%) | 81% |
|
| Liabilities to Assets | 28.1% | 29.7% | 20% |
|
| F-Score | 7 | 3 | 82% |
|
Puma Biotechnology, Inc. did not pass any screens on 9/10/2026.
